-
Reata Pharmaceuticals – Omaveloxolone Update #3
Today, Reata Pharmaceuticals provided a 4th quarter and full year 2020 update on clinical programs. During this meeting, Reata acknowledged the FA Community petition to advance regulator approval of omaveloxolone in FA. Reata also presented additional data from the extension study that supports a disease modifying effect of omav. Reata is reaching out to FDA to request a Type C meeting to continue dialogue on regulatory path forward.
To read the full press release or listen to the call, click below: http://bit.ly/3dZ9xVI
-
2 Replies
-
Today we had our check up with the neurologist and she said that the FDA did not approve the Omaveloxolone, is this right? but I believe there was a letter signed by patients and relatives asking for this. We live in Spain but I try to follow the updates. Thank you so much
-
This is correct. FARA and Reata js hoping the signed petition will help quicken use approval process.
Log in to reply.